CFD'er er komplekse instrumenter, og der er stor risiko for at miste penge hurtigt på grund af gearing. 84% af individuelle investorer taber penge, når de handler CFD'er med denne udbyder. Du bør overveje, om du forstår, hvordan CFD'er virker, og om du har råd til at løbe en høj risiko for at miste dine penge.
Capital Com Australia Pty Ltd Reguleret af ASIC Capital Com UK Limited Reguleret af Financial Conduct Authority (FCA) Capital Com SV Investments Limited Reguleret af CYSEC Сlosed Joint Stock Company «FinTech Solutions» Reguleret af NBRB Smart Forex Broker LLC Capital Com Stock and CFD Investing Ltd Reguleret af FSA Capital Com Online Investments Ltd Reguleret af SCB Our Global Offices

Scan to Download iOS&Android APP

English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文
Du kan også kontakte os: ring +44 2030978888 support@capital.com

Handel Angion Biomedica Corp. - ANGN CFD

0.5279
0%
  • Opsummering
  • Historisk Data
  • Begivenheder
  • Resultatopgørelse
  • Saldo
  • Cash flow
  • Ejerskab
Handelsbetingelser
Spænd 0.0341
Long position, gebyr natten over

Long position overnight fee

Margin. Your investment $1,000.00
Gebyr for natten over -0.024068 %
Charges from borrowed part ($-0.96)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
Gå til platform
-0.024068%
Short position, gebyr natten over

Short position overnight fee

Margin. Your investment $1,000.00
Gebyr for natten over 0.001846 %
Charges from borrowed part ($0.07)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
Gå til platform
0.001846%
Gebyr natten over, tid 21:00 (UTC)
Min. handlet mængde 1
Valuta USD
Margen 20%
Aktiebørs United States of America
Kommission på handel 0%

*Information provided by Capital.com

Nøglestatistikker
Tidligere luk* 0.4887
Åben* 0.4791
1-Års Ændring* -76.97%
Dagens Spænd* 0.4791 - 0.489
52-Ugers Spænd 0.46-2.41
Gennemsnitlig Volumen (10 dage) 28.11K
Gennemsnitlig Volumen (3 måneder) 1.42M
Market Cap 14.76M
P/E-forhold -100.00K
Udestående aktier 30.11M
Omsætning 2.30M
EPS -1.29
Dividend (Udbytte %) N/A
Beta -100.00K
Næste indtjeningsopgørelse Mar 28, 2023

Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Luk Change Change (%) Åben High Low
Mar 22, 2023 0.4887 0.0096 2.00% 0.4791 0.4890 0.4791
Mar 21, 2023 0.4789 0.0248 5.46% 0.4541 0.4791 0.4493
Mar 20, 2023 0.4881 0.0001 0.02% 0.4880 0.4986 0.4739
Mar 17, 2023 0.4887 -0.0490 -9.11% 0.5377 0.5378 0.4823
Mar 16, 2023 0.5081 0.0198 4.05% 0.4883 0.5695 0.4883
Mar 15, 2023 0.4930 -0.0542 -9.90% 0.5472 0.5671 0.4888
Mar 14, 2023 0.5372 -0.0196 -3.52% 0.5568 0.5963 0.5372
Mar 13, 2023 0.5377 -0.0240 -4.27% 0.5617 0.5621 0.5208
Mar 10, 2023 0.5132 -0.0641 -11.10% 0.5773 0.5778 0.5054
Mar 9, 2023 0.5568 -0.0604 -9.79% 0.6172 0.6256 0.5375
Mar 8, 2023 0.5960 0.0078 1.33% 0.5882 0.6158 0.5882
Mar 7, 2023 0.6060 -0.0094 -1.53% 0.6154 0.6155 0.6056
Mar 6, 2023 0.6256 -0.0208 -3.22% 0.6464 0.6466 0.6079
Mar 3, 2023 0.6156 0.0290 4.94% 0.5866 0.6258 0.5865
Mar 2, 2023 0.5969 0.0009 0.15% 0.5960 0.6130 0.5960
Mar 1, 2023 0.5883 -0.0370 -5.92% 0.6253 0.6256 0.5855
Feb 28, 2023 0.6258 0.0006 0.10% 0.6252 0.6452 0.6252
Feb 27, 2023 0.6453 0.0001 0.02% 0.6452 0.6454 0.6451
Feb 24, 2023 0.6455 0.0006 0.09% 0.6449 0.6736 0.6264
Feb 23, 2023 0.6449 -0.0001 -0.02% 0.6450 0.6454 0.6367

Angion Biomedica Corp. Events

Tid (UTC) (UTC) Land Begivenhed
No events scheduled
Se alle begivenheder
  • Årlig
  • Pr kvartal
2021 2020 2019 2018
Total omsætning 28.312 2.88 1.487 4.029
Omsætning 28.312 2.88 1.487 4.029
Kost af omsætning, Total 0.433 1.19 0.64 0.378
Bruttofortjeneste 27.879 1.69 0.847 3.651
Totale Driftsudgifter 66.714 58.153 40.078 18.371
Salgs/Generelle/Admin. Udgifter, Total 18.488 17.986 9.601 5.391
Forskning & Udvikling 48.698 38.977 29.837 12.602
Driftsindtægter -38.402 -55.273 -38.591 -14.342
Renteindkomst (Udgift), Netto Ikke-Drift -2.191 -8.249 0.488 0.401
Andre, Netto -13.98 -16.527 -2.555 -6.084
Netto Indkomst Før Skat -54.573 -80.107 -40.658 -20.025
Netto Indkomst Efter Skat -54.573 -80.107 -40.658 -20.025
Netto Indkomst Før Ekstra Ting -54.573 -80.107 -40.658 -20.025
Netto Indkomst -54.573 -80.107 -40.658 -20.025
Total Adjustments to Net Income 0 -4.98
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -54.573 -80.107 -40.658 -25.005
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -54.573 -80.107 -40.658 -25.005
Fortyndet Netto Indkomst -54.573 -80.107 -40.658 -25.005
Fortyndet Vægtet Gennemsnit Aktier 28.2448 14.7621 9.97635 9.97635
Fortyndet EPS Uden Ekstraordinære Ting -1.93214 -5.42652 -4.07544 -2.50643
Dividends per Share - Common Stock Primary Issue 0 0
Fortyndet Normaliseret EPS -1.96418 -5.4226 -4.07544 -2.50643
Gain (Loss) on Sale of Assets 0 -0.058
Usædvanlig Udgift (Indkomst) -0.905
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total omsætning 1.648 25.941 1.46 0.54 0.371
Omsætning 1.648 25.941 1.46 0.54 0.371
Kost af omsætning, Total 0.433 0 0 0
Bruttofortjeneste 25.508 1.46 0.54 0.371
Totale Driftsudgifter 16.133 11.307 17.218 17.879 20.31
Salgs/Generelle/Admin. Udgifter, Total 4.466 4.206 3.93 4.34 6.012
Forskning & Udvikling 11.667 6.668 13.288 14.444 14.298
Driftsindtægter -14.485 14.634 -15.758 -17.339 -19.939
Renteindkomst (Udgift), Netto Ikke-Drift 0.206 -0.016 -0.074 0.067 -2.168
Andre, Netto 0.039 0.272 0.128 0.2 -14.58
Netto Indkomst Før Skat -14.24 14.89 -15.704 -17.072 -36.687
Netto Indkomst Efter Skat -14.24 14.89 -15.704 -17.072 -36.687
Netto Indkomst Før Ekstra Ting -14.24 14.89 -15.704 -17.072 -36.687
Netto Indkomst -14.24 14.89 -15.704 -17.072 -36.687
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -14.24 14.89 -15.704 -17.072 -36.687
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -14.24 14.89 -15.704 -17.072 -36.687
Fortyndet Netto Indkomst -14.24 14.89 -15.704 -17.072 -36.687
Fortyndet Vægtet Gennemsnit Aktier 29.9592 29.9654 29.8296 29.6703 23.4438
Fortyndet EPS Uden Ekstraordinære Ting -0.47531 0.49691 -0.52646 -0.57539 -1.56489
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Fortyndet Normaliseret EPS -0.47531 0.49691 -0.52646 -0.60589 -1.56489
Usædvanlig Udgift (Indkomst) 0 0 -0.905
Gain (Loss) on Sale of Assets 0
  • Årlig
  • Pr kvartal
2021 2020 2019 2018
Totale Nuværende Aktiver 91.247 42.297 6.106 25.679
Likvider og Kortsigtede Investeringer 88.756 34.607 5.571 25.512
Likvider & Lignende 88.756 34.607 5.571 25.512
Totale Tilgodehavender, Netto 0.806 5 0.44 0.107
Prepaid Expenses 1.031 0.352 0.095 0.06
Total Assets 96.513 47.347 11.886 26.628
Property/Plant/Equipment, Total - Net 4.437 4.228 4.781 0.017
Property/Plant/Equipment, Total - Gross 4.954 4.654 5.109 0.295
Accumulated Depreciation, Total -0.517 -0.426 -0.328 -0.278
Long Term Investments 0.723 0.822 0.999 0.932
Total Current Liabilities 11.296 107.449 26.575 7.355
Accounts Payable 4.71 5.578 11.239 0.534
Accrued Expenses 4.113 7.276 3.694 2.98
Notes Payable/Short Term Debt 0 51.43 5.848 0
Other Current Liabilities, Total 2.415 43.165 5.794 3.841
Total Liabilities 15.006 137.796 30.472 7.717
Total Long Term Debt 0.235 0.635 0 0
Other Liabilities, Total 3.475 29.712 3.897 0.362
Total Equity 81.507 -90.449 -18.586 18.911
Preferred Stock - Non Redeemable, Net 0 0 0
Common Stock 0.3 0.156 0.095 0.094
Additional Paid-In Capital 296.445 72.136 63.584 60.138
Retained Earnings (Accumulated Deficit) -215.135 -160.562 -80.455 -39.797
Treasury Stock - Common 0 -1.846 -1.81 -1.524
Total Liabilities & Shareholders’ Equity 96.513 47.347 11.886 26.628
Total Common Shares Outstanding 29.9591 15.3167 9.97635 9.97635
Other Current Assets, Total 0.654 2.338
Long Term Debt 0 0.635
Other Equity, Total -0.103 -0.333
Other Long Term Assets, Total 0.106
Current Port. of LT Debt/Capital Leases 0.058
Capital Lease Obligations 0.235
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Totale Nuværende Aktiver 76.239 91.247 104.393 119.702 133.498
Likvider og Kortsigtede Investeringer 73.002 88.756 102.736 117.313 130.456
Likvider & Lignende 73.002 88.756 102.736 117.313 130.456
Totale Tilgodehavender, Netto 0 0.806 0 0 0
Prepaid Expenses 0.021 1.031 1.018 1.761 2.343
Other Current Assets, Total 3.216 0.654 0.639 0.628 0.699
Total Assets 81.258 96.513 109.94 125.359 139.2
Property/Plant/Equipment, Total - Net 4.209 4.437 4.652 4.776 4.787
Property/Plant/Equipment, Total - Gross 4.758 4.954 5.137 5.231 5.219
Accumulated Depreciation, Total -0.549 -0.517 -0.485 -0.455 -0.432
Long Term Investments 0.732 0.723 0.862 0.843 0.877
Other Long Term Assets, Total 0.078 0.106 0.033 0.038 0.038
Total Current Liabilities 10.381 11.296 17.946 20.524 16.963
Accounts Payable 3.433 4.71 7.679 9.307 6.69
Accrued Expenses 6.16 4.113 6.219 5.522 4.872
Notes Payable/Short Term Debt 0 0 0 0 0.895
Other Current Liabilities, Total 0.728 2.415 4.048 5.695 4.506
Total Liabilities 14.056 15.006 45.426 48.17 46.757
Total Long Term Debt 0.219 0.235 0 0 0
Long Term Debt 0 0 0 0
Other Liabilities, Total 3.456 3.475 27.48 27.646 29.794
Total Equity 67.202 81.507 64.514 77.189 92.443
Common Stock 0.3 0.3 0.304 0.303 0.3
Additional Paid-In Capital 296.476 296.445 298.518 295.636 292.67
Retained Earnings (Accumulated Deficit) -229.375 -215.135 -230.025 -214.321 -197.249
Treasury Stock - Common 0 -4.21 -4.21 -2.991
Other Equity, Total -0.199 -0.103 -0.073 -0.219 -0.287
Total Liabilities & Shareholders’ Equity 81.258 96.513 109.94 125.359 139.2
Total Common Shares Outstanding 29.9594 29.9591 29.9331 29.7976 29.6605
Current Port. of LT Debt/Capital Leases 0.06 0.058
Capital Lease Obligations 0.219 0.235
  • Årlig
  • Pr kvartal
2021 2020 2019 2018
Netto indkomst/Startlinje -54.573 -80.107 -40.658 -20.025
Likvider Fra Driftsaktiviteter -52.643 -22.888 -24.589 -8.02
Likvider Fra Driftsaktiviteter 0.091 0.098 0.05 0.002
Ikke-Likvide Ting 27.809 31.352 6.269 9.051
Cash Taxes Paid 0 0
Likvid Rente Betalt 0.007 0 0
Ændringer i Driftskapital -25.97 25.769 9.75 2.952
Likvider fra Investeringsaktiviteter -0.382 -0.041 -0.242 0
Kapitaludgifter -0.382 -0.041 -0.242 0
Likvider fra Financieringsaktiviteter 107.171 52.409 4.89 31.741
Udstedelse (Pensionering) af Aktier, Netto -0.617 20.813 -0.375 28.596
Udstedelse (Pensionering) af Gæld, Netto 0.293 32.118 5.265 3.145
Netto Ændring i Likviditet 54.149 29.036 -19.941 23.721
Financiering af Cash-Flow-Ting 107.495 -0.522
Udenlandsk Børs Effekter 0.003 -0.444
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -14.24 -54.573 -69.463 -53.759 -36.687
Cash From Operating Activities -15.653 -52.643 -38.281 -23.082 -12.551
Cash From Operating Activities 0.032 0.091 0.059 0.029 0.006
Non-Cash Items 0.179 27.809 25.729 23.505 21.675
Changes in Working Capital -1.624 -25.97 5.394 7.143 2.455
Cash From Investing Activities 0 -0.382 -0.346 -0.285 -0.041
Capital Expenditures 0 -0.382 -0.346 -0.285 -0.041
Cash From Financing Activities -0.014 107.171 106.767 106.068 108.444
Financing Cash Flow Items 0 107.495 -5.52 -5.428 -2.797
Issuance (Retirement) of Stock, Net 0 -0.617 112.287 111.496 111.241
Issuance (Retirement) of Debt, Net -0.014 0.293 0 0 0
Foreign Exchange Effects -0.087 0.003 -0.011 0.005 -0.003
Net Change in Cash -15.754 54.149 68.129 82.706 95.849
Cash Interest Paid 0.007
Investornavn Investortype Procent udestående Aktiebeholdning Aktieændring Beholdningsdato IOmsætningsscore
Satterfield (Thomas A Jr) Individual Investor 7.2983 2197825 623278 2022-12-31 LOW
Vifor (International), Ltd Corporation 6.6269 1995643 0 2023-03-15 LOW
EISA-ABC LLC Corporation 5.719 1722237 0 2023-03-15 LOW
Goldberg (Itzhak D) Individual Investor 5.6193 1692199 4213 2023-03-15 LOW
Venkatesan (Jay R) Individual Investor 3.9765 1197498 0 2023-03-15 LOW
BVF Partners L.P. Hedge Fund 3.5574 1071297 0 2022-12-31 LOW
Nantahala Capital Management, LLC Hedge Fund 3.4308 1033145 -32867 2022-12-31 MED
Ganzi (Victor F.) Individual Investor 3.25 978698 0 2023-03-15 LOW
CM Management, LLC Investment Advisor 2.4313 732178 132178 2022-12-31 MED
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.1386 644035 675 2022-12-31 LOW
Park West Asset Management LLC Hedge Fund 1.2311 370724 0 2022-12-31 MED
Bridgeway Capital Management, LLC Investment Advisor 0.5811 175000 0 2022-12-31 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.5593 168436 -451 2022-12-31 LOW
Renaissance Technologies LLC Hedge Fund 0.4041 121700 -87277 2022-12-31 HIGH
Omenn (Gilbert S) Individual Investor 0.2667 80326 0 2023-03-15 LOW
Millennium Management LLC Hedge Fund 0.2502 75342 -50261 2022-12-31 HIGH
Raymond James & Associates, Inc. Research Firm 0.1992 60000 0 2022-12-31 LOW
Birchview Capital, LP Investment Advisor 0.1806 54392 0 2022-12-31 LOW
Ergoteles Capital Hedge Fund 0.1757 52913 -25944 2022-12-31 HIGH
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.1696 51069 1188 2022-12-31 LOW

Hvorfor vælge Capital.com? Vores tal taler for sig selv.

Capital.com Group

500K+

Handlende

92K+

Månedlkige, aktive klienter

$53M+

Månedlig investeringsvolumen

$30M+

Hævet hver måned

Handelslommeregner

Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).

Handelskurtage
0
  • 1:1
Gearing
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben

Luk

Short Long
Tidligere resultater er ikke en pålidelig indikator for fremtidige resultater
Fortjeneste/Tab

Angion Biomedica Corp. Company profile

Om Angion Biomedica Corp.

Angion Biomedica Corp. er en biofarmaceutisk virksomhed i den sene fase. Virksomheden fokuserer på opdagelse, udvikling og kommercialisering af små molekylære terapier til behandling af akutte organskader og fibrotiske sygdomme. Virksomhedens førende produktkandidat er ANG-3777. Selskabets pipeline omfatter ANG-3070, rho kinase 2 (ROCK2) og CYP11B2. ANG-3777 er et hepatocytvækstfaktor (HGF)-mimetikum, som virksomheden er ved at evaluere i forbindelse med flere akutte organskader og relaterede indikationer, herunder akut nyreskade (AKI) og skader på andre organer, såsom lunger, centralnervesystemet (CNS) og hjertet. ANG-3777 evalueres også til indikationer inden for akut lungeskade (ALI) med fokus på akut respiratorisk distress syndrom (ARDS) samt akutte CNS-skader. Selskabets andre programmer er til behandling af fibrotiske sygdomme, ANG-3070, en tyrosinkinasehæmmer (TKI), og en hæmmer af rho kinase 2 (ROCK2).

Industry: Biotechnology & Medical Research (NEC)

7-57 Wells Avenue
NEWTON
MASSACHUSETTS 02459
US

Resultatopgørelse

  • Annual
  • Quarterly

Folk ser også

Oil - Crude

70.45 Price
+0.690% 1D Chg, %
Long position, gebyr natten over -0.0170%
Short position, gebyr natten over -0.0050%
Gebyr natten over, tid 21:00 (UTC)
Spænd 0.03

XRP/USD

0.45 Price
+5.740% 1D Chg, %
Long position, gebyr natten over -0.0753%
Short position, gebyr natten over 0.0069%
Gebyr natten over, tid 21:00 (UTC)
Spænd 0.00449

BTC/USD

27,577.70 Price
+0.520% 1D Chg, %
Long position, gebyr natten over -0.0616%
Short position, gebyr natten over 0.0137%
Gebyr natten over, tid 21:00 (UTC)
Spænd 60.00

Gold

1,972.13 Price
+0.190% 1D Chg, %
Long position, gebyr natten over -0.0086%
Short position, gebyr natten over 0.0004%
Gebyr natten over, tid 21:00 (UTC)
Spænd 0.30

Leder du stadig efter en mægler, du kan stole på?

Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com

1. Opret og bekræft din konto 2. Lav en inddbetaling 3. Find din handel